Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.7252W HIGH $1,201.59
Volume
9.43 K
Value Traded
16.79 K
Short % Float
2.1%
-4.15%Week
-4.55%1 Month
+111.93%3 Month
-17.5%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
100.81 M
EPS (TTM)
-8.16
P/E Ratio
-
Ent. Value
102.96 M
Total Shares
21.82 M
Float Shares
5.94 M
Insiders
72.77%
Institutions
0.32%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ZSTK Catalyst Timeline
Dated clinical, regulatory and corporate events for ZeroStack Corp.
Past FDA Catalysts and PDUFA Decisions
How ZSTK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ZSTK program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rong RudyOfficer (President) | Sell | -1,000 | $7.57 | 08/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ZSTK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ZSTK for Q2 2026. | ||||
ZSTK Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ZSTK ranks across every disease it competes in
Competitive Position is a premium feature
See how ZSTK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialZSTK News
ZSTKTransparency First: An Update on ZeroStack's Financials and Progress
ZeroStack has provided an update on its financials and progress, highlighting the receipt of over $401 million in funding. Significant contributions come from both digital assets and cash raises, including a successful launch of the $0G token. The company emphasized transparency with its community about its financial undertakings and future plans in decentralized AI. Leadership changes were also announced to guide the company's long-term vision.
Read more →ZSTKFiled by newsfilecorp.com Flora Growth Corp. Unaudited Pro Forma Consolidated Financial Statements (United States Dollars, unless otherwise noted)
Flora Growth Corp. has filed unaudited pro forma consolidated financial statements reflecting the financial position as of June 30, 2025. These statements show the impact of the recent disposition of its cannabis-related businesses. The financial adjustments indicate significant losses and a substantial accumulated deficit. The results also suggest a need for the company to navigate its financial future carefully following this major transaction.
Read more →ZSTKFiled by newsfilecorp.com Flora Growth Corp. Announces Pricing of $2.7 Million Registered Direct Offering and Concurrent Private Placement
Flora Growth Corp. has announced a registered direct offering and concurrent private placement, totaling $2.7 million, with institutional investors purchasing 1,369,000 common shares and warrants. The offering is expected to close by September 21, 2023, contingent on customary conditions. The raised capital will be allocated to enhance operating capacity and for general corporate purposes. Additionally, the company plans to amend terms for previously issued warrants for certain investors in conjunction with this offering.
Read more →ZSTKFiled by newsfilecorp.com Flora Growth Corp. to Acquire Australian Vaporizers; Expects Immediate Profit Contribution
Flora Growth Corp. has entered into a definitive agreement to acquire Australian Vaporizers Pty Limited for 600,676 common shares, valued at $1.7 million. This acquisition, anticipated to close in Q4 2023, is expected to immediately contribute $5.2 million in revenues and $0.5 million in net income. Australian Vaporizers, a prominent retailer in Australia, has a strong track record with over 30,000 active customers. CEO Clifford Starke highlighted the acquisition's potential synergies with Flora's existing brands.
Read more →ZSTKFiled by newsfilecorp.com Flora Growth Corp. Unaudited Pro Forma Consolidated Statement of Loss and Comprehensive Loss (Stated in Thousands of United States Dollars)
Flora Growth Corp. has released its unaudited pro forma consolidated statement of loss for the year ending December 31, 2022, indicating substantial financial losses following the acquisition of Franchise Global Health Inc. The report reveals a net loss of approximately $75.6 million and significant operating expenses totaling over $81 million. The financial statement is intended for inclusion in the company's registration statement and does not predict the future performance or stability of the combined entity following the acquisition. The assumptions underlying the pro forma adjustments remain speculative, raising concerns about the company's financial outlook.
Read more →ZSTKFiled by newsfilecorp.com Flora Growth Corp. Reports Second Quarter 2023 Financial Results
Flora Growth Corp. reported its financial results for the second quarter of 2023, indicating a year-over-year revenue increase of 140% to $21.5 million. Despite the positive revenue growth, the company experienced a significant net loss of $44.6 million, primarily due to impairment and losses from discontinued operations. The CEO highlighted ongoing efforts in cost reduction and resource optimization as part of the company's transitional phase. Additionally, a board member's resignation was noted, marking a potential shift in company dynamics.
Read more →ZSTKFiled by newsfilecorp.com Flora Growth Corp. Announces Update on Sale of Colombian Assets; Expects Asset Sale to Contribute to Anticipated Annual Savings of US$6.1 million FORT LAUDERDALE, FLORIDA & TORONTO, ONTARIO
Flora Growth Corp. has announced the sale of its Colombian assets to a private company for C$0.8 million, aimed at achieving strategic cost reductions of US$6.1 million annually. The sale encompasses Flora's operations in Colombia, including a significant farm and various processing facilities. Despite the anticipated cost savings, the company has advised that its previously issued revenue guidance may no longer be reliable, and updated forecasts will be provided soon. Additionally, the company's General Counsel has resigned, raising concerns about leadership stability.
Read more →ZSTKFlora Growth Corp. appoints Clifford Starke as Chief Executive Officer and Dany Vaiman as Chief Financial Officer; Regains compliance with NASDAQ minimum bid requirement
Flora Growth Corp. has appointed Clifford Starke as CEO and Dany Vaiman as CFO while regaining compliance with NASDAQ's minimum bid requirement. Mr. Starke's leadership aims to capitalize on the growth opportunities in the cannabis sector, particularly in international markets. The company has a robust distribution network across 28 countries, providing a strategic foundation for expansion. However, the firm faces challenges such as past executive resignations and existing struggles within the cannabis industry related to policy and market conditions.
Read more →ZSTKFlora Growth Corp. to Effect Reverse Stock Split FORT LAUDERDALE, FLORIDA & TORONTO
Flora Growth Corp. has announced a reverse stock split at a ratio of 1-for-20, effective June 9, 2023. This decision was approved by shareholders during a recent meeting. The common shares will continue to trade under the existing ticker FLGC on the Nasdaq Capital Market. While the reverse stock split does not affect ownership percentages or voting rights, it does raise concerns over potential volatility and expectations surrounding future performance.
Read more →ZSTKFlora Growth Reports First Quarter 2023 Financial Results Flora generated $20.1 million in revenue in Q1 2023, a 307% increase year-over-year. Gross profit for Q1 2023 increased 105% year-over-year, to $5.5 million. Post
Flora Growth Corp. reported impressive financial results for Q1 2023, with revenue reaching $20.1 million, a 307% increase from the previous year. Gross profit also saw a significant rise of 105%, although the company faced a net loss of $3.9 million. CEO Hussein Rakine acknowledged challenges such as export delays and high operating expenses, which impacted liquidity. Efforts to optimize operations and reduce costs are ongoing as the company aims to enhance shareholder value in the future.
Read more →ZSTKFlora Growth Corp. Announces the Appointment of Hussein Rakine as CEO and Member of the Board of Directors
Flora Growth Corp. has announced the appointment of Hussein Rakine as CEO, following the resignation of Luis Merchan. Rakine, the founder of Just Brands, aims to lead the company through its next growth phase, highlighting the significant potential in the cannabis market. Merchan will assist with the transition and emphasized confidence in Flora's future. The company continues to commit to long-term success in the cannabis industry, noting the optimistic outlook due to changing global policies.
Read more →ZSTKFlora Growth Reports 2022 Year-End Financial Results: $37.2M in Revenue, 314% Growth Year-Over-Year Flora generated $37.2 million in revenue in FY2022, a 314% increase YoY Record Q4 2022 revenue increased to $11.5 millio
Flora Growth Corp. reported its 2022 financial results, showing substantial growth with a revenue of $37.2 million, marking a 314% increase year-over-year. Gross profit also rose significantly by 494%, reaching $14.4 million, contributing to a positive outlook for the company. Flora reaffirmed its 2023 revenue guidance of $90 million to $105 million, anticipating continued growth from its House of Brands and Commercial divisions. However, the company also reported an adjusted EBITDA loss and a net loss for the year, raising some concerns about long-term profitability.
Read more →ZSTKFlora Growth Issues 2023 Revenue Guidance of $90 Million to $105 Million Reflecting Anticipated Year Over Year Growth Exceeding 100% - Flora will host a webcast discussing 2023 guidance and recapping 2022 milestones at 4
Flora Growth Corp. has announced a revenue guidance ranging from $90 million to $105 million for the fiscal year 2023, indicating over 100% year-over-year growth. This forecast is supported by initiatives in their House of Brands and Commercial & Wholesale divisions, as well as the acquisition of Franchise Global Health. Flora also highlights its successful expansion into international markets and new product offerings. The announcement follows a positive performance in 2022, reflecting the company's strategic growth amid industry challenges.
Read more →ZSTKFlora Growth Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule FORT LAUDERDALE, FLORIDA, TORONTO, ONTARIO
Flora Growth Corp. has been granted an additional 180 days by Nasdaq to regain compliance with its minimum bid price requirement of $1.00 per share. This extension follows the expiration of a previous compliance period and allows the company until July 3, 2023, to meet this requirement, potentially through a reverse stock split. If the bid price does not rise above $1.00 within this timeframe, the company may face delisting, although it can appeal any such decision while remaining listed. The current notification has no immediate impact on share trading.
Read more →ZSTKFlora Growth Closes Acquisition of Franchise Global Health, Cementing Foothold in Germany and the European Union The transformative acquisition is expected to connect Flora Growth's Colombian-grown cannabis directly with
flora_ex991.htm EXHIBIT 99.1 Flora Growth Closes Acquisition of Franchise Global Health, Cementing Foothold in Germany and the The transformative acquisition is expected to connect Flora Growth's Colombian-grown cannabis directly with German-based pharmaceutical and medical
Read more →ZSTKFlora Growth Corp. Announces Pricing of $5.0 Million Registered Direct Offering FORT LAUDERDALE, FLORIDA & TORONTO
flora_ex991.htm EXHIBIT 99.1 Flora Growth Corp. Announces Pricing of $5.0 Million Registered Direct Offering FORT LAUDERDALE, FLORIDA & TORONTO, December 9, 2022--(BUSINESS WIRE)--Flora Growth Corp. (NASDAQ: FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, m
Read more →ZSTKFlora Growth Reports Third Quarter 2022 Financial Results Revenue for the three-month period ended
flora_ex991.htm EXHIBIT 99.1 Flora Growth Reports Third Quarter 2022 Financial Results Revenue for the three-month period ended September 30, 2022 was $10.8 million, an increase of 414% year over year Revenue for the nine-month period ended September 30, 2022 was $25.7 mill
Read more →ZSTKARRANGEMENT AGREEMENT FLORA GROWTH CORP. - and
ARRANGEMENT AGREEMENT, DATED OCTOBER 21, 2022 flora_ex991.htm EXHIBIT 99.1 ARRANGEMENT AGREEMENT FRANCHISE GLOBAL HEALTH INC. _________________________ ARTICLE 1 INTERPRETATION 2 1.1. Defined Terms 2 1.2. Certain Rules of Interpretation 15 1.3. Schedules 16 ARTICLE 2 THE
Read more →ZSTKFlora Growth Corp. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended June 30, 2022 and 2021 (Expressed in United States Dollars) Flora Growth Corp. Interim Condensed Consolidated Statements of Financial Position (Unaudited - Prepared by Management) (in thousands
Read more →ZSTKFlora Growth Reports H1 2022 Financial Results H1 2022 revenue increased to ~$15.0 million, up 604% from H1 2021 and 117% from H2 2021, driven by House of Brands Gross Profit increased to ~$7.0 million, up 547% compared
flora_ex991.htm EXHIBIT 99.1 Flora Growth Reports H1 2022 Financial Results H1 2022 revenue increased to ~$15.0 million, up 604% from H1 2021 and 117% from H2 2021, driven by House of Brands Gross Profit increased to ~$7.0 million, up 547% compared to H1 2021 and 363% compa
Read more →About ZeroStack Corp.
Headquarters2626 COLE AVENUE, SUITE 300, DALLAS, TX, 75204
BIOPHARMAWATCH ELITE PLUS
Trade the next ZSTK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime